Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Technologies' OneSeq

Agilent Technologies has launched OneSeq, an all-in-one target enrichment product for next-generation sequencing. OneSeq is designed to detect and analyze copy number variations, loss of heterozygosity, and mutations in a single reaction for use in constitutional disease research. Powered by the company's SureSelect target enrichment platform, OneSeq will help laboratories involved in cytogenetic research save time gathering and analyzing complex, multifactorial data, Agilent said.

Agilent showcased the technology at the Advances in Genome Biology and Technology conference in Marco Island, Fla., this week.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.